AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04774458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluoroscopic-guided cervical epidural access
Description: After identifying the target level of the cervical spine under a fluoroscopy-guided anteroposterior image, an 18-Tuohy needle is inserted through a paramedian approach after local infiltration with 1% lidocaine. When feeling a strong resistance through the needle by a ligamentum flavum, the image intensifier is rotated to 50 degrees contralateral oblique (CLO) direction. After then, the needle is advanced to just before the ventral interlaminar line in CLO view. It is subsequently advanced further until it is in the epidural space using a LOR-to-air technique. Correct epidural access is confirmed by the injection of contrast medium. After identifying epidural space in AP and CLO view without abnormal dispersion of contrast,(vascular uptake, intrathecal spreads, etc.), a 3-4ml mixture of 0.5% lidocaine with dexamethasone 5mg is injected.
Study NCT06657209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OGTT
Description: Will collect 5 blood draws during the test to measure insulin secretion
Study NCT06657209 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fat biopsy
Description: Needle biopsy to gather a sample of abdominal subcutaneous fat
Study NCT06657209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat biopsy
Description: Needle biopsy to gather a sample of abdominal subcutaneous fat
Study NCT06657209 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: DXA scan
Description: Whole body DXA scan
Study NCT06657209 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DXA scan
Description: Whole body DXA scan
Study NCT06657209 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: Abdominal MRI
Study NCT06657209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Abdominal MRI
Study NCT06657209 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 1H-MRS
Description: Spectroscopy of the abdominal region
Study NCT06657209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1H-MRS
Description: Spectroscopy of the abdominal region
Study NCT06657209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: 16 weeks started at 2.5mg/week and increased to 5mg/week dose
Study NCT06657209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 16 weeks at a 45mg/day dose
Study NCT05113693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393
Description: QD, PO
Study NCT05444127 — intervention group
Intervention type: OTHER
Intervention: Questionnaire OHIP-14
Description: A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
Study NCT05113693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D759, H053
Description: QD, PO
Study NCT05444127 — intervention group
Intervention type: OTHER
Intervention: Thorough dental examination
Description: A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
Study NCT06042335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAISe EZ
Description: DAISe Thrombectomy System for mechanical thrombectomy
Study NCT04561180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-009A
Description: Administered as an Intramuscular injection
Study NCT04561180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EG-009A Placebo
Description: Administered as an Intramuscular injection
Study NCT04561180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection
Study NCT04561180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection
Study NCT04561180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: The comparator, Administered as an Intravenous infusion
Study NCT04561180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: The comparator, Administered as an Intravenous infusion
Study NCT04613206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose Quadrivalent Inactivated Influenza Vaccine
Description: Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration.
Study NCT04613206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard Dose Quadrivalent Inactivated Influenza Vaccine
Description: Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
Study NCT04985565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Participate in Mediterranean diet
Study NCT04533269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arnica montana, Ledum palustre
Description: Homeopathic
Study NCT04533269 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Arnica montana, Ledum palustre
Description: Homeopathic
Study NCT04985565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo standard of care radical prostatectomy
Study NCT06250309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary assignment
Description: A total of 48 subjects will be randomized by a computer program into one of two groups: MD or WD. Participation in each dietary arm lasts 8 weeks, with a 6 week washout period in between each arm.
Study NCT04826718 — intervention group
Intervention type: OTHER
Intervention: Questionaire
Description: A questionnaire will be administered to all participants to evaluate exposures related to infection at the baseline (enrollement) - Baseline questionnaire. A Follow-up questionnaire to all participants will be done after 3 and 6 months.~Capillary blood collection, for diagnosis of anti-SARS-CoV-2 Antibodies by rapid test, will be done at the first interview, for all participants (cases and controls).~Collection of peripheral venous blood, for analysis of the presence and duration of anti-SARS-CoV-2 Antibodies (N and S) will be done at the first interview, and after 6 months for all participants (cases and controls).
Study NCT06406608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
Description: This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
Study NCT04166734 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab will be continued dosed at 200 mg given every 3 weeks~Drug: Pembrolizumab Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
Study NCT04166734 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)
Study NCT05253950 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: answered questions from two standard questionnaires the Internet Addiction Test (IAT) which examines students' dependence on the internet and the Nordic Muscuskeletal Questionnaire (NQS) which examines the onset of symptoms from the musculoskeletal system
Study NCT04391621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Derived stem cell transplantation
Description: Through liposuction, harvested lipoaspirate will be processed in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for inflitration. This will then be infiltrated into the affected keloid.
Study NCT04391621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1
Description: Triamcinolone Acetanoide 40mg/ml suspension will be diluted into 1ml of 0.5% lignocaine solution and infiltrated into the selected keloid.
Study NCT05546138 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin biopsies with quantification of intra-epidermal nerve fibre density
Description: Skin biopsy
Study NCT05546138 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Perception Threshold Tracking
Description: Transcutaneous stimulation of large and small nerve fibres using weak electrical currents
Study NCT05546138 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thermal perception thresholds
Description: Heat and cold perception thresholds
Study NCT05546138 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Corneal confocal Microscopy
Description: Corneal nerve fibre density, corneal nerve fibre length, corneal nerve branch density
Study NCT05546138 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Functional and structural MRI pictures of peripheral nerves and CNS
Study NCT05546138 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve conduction studies
Description: Nerve conduction and amplitude of Sural nerve
Study NCT05546138 — intervention group
Intervention type: OTHER
Intervention: Composite scores and questionnaires
Description: Composite scores and questionnaires
Study NCT05357729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MultiSense® remote monitoring
Description: At hospital, the patient will be monitored with conventional monitoring devices as well as the MultiSense® solution (at least one hour with a reference monitor). After hospital discharge, the patients will be remotely monitored by their healthcare professional using the MultiSense® solution.
Study NCT05275998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMB-365/TMB-380
Description: Monoclonal antibodies to be given intravenously
Study NCT04916548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Ketamine
Description: Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
Study NCT05743582 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy for sample collection
Description: Participants will undergo a single bronchoscopy and bronchoalveolar lavage to obtain immune cells.
Study NCT04724941 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06097819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile app-based game group
Description: Mobile app based game therapy+Occupational therapy+Sensor-based game therapy
Study NCT06097819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised combined sensor-based game group
Description: Occupational therapy+Sensor-based game therapy
Study NCT06097819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized occupational therapy group
Description: Occupational therapy
Study NCT05900635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Description: Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients
Study NCT05900635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Glycine Sulfate
Description: Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients
Study NCT05900635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Glycine Sulfate
Description: Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients
Study NCT05743582 — intervention group
Intervention type: PROCEDURE
Intervention: Blood donation
Description: Participants will donate a single blood sample for isolation of immune cells from peripheral blood.
Study NCT05574049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetrahydrocannabivarin
Description: The subjects will take once daily oromucosal strip with intervention drug for 90 days.
Study NCT05574049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tetrahydrocannabivarin
Description: The subjects will take once daily oromucosal strip with intervention drug for 90 days.
Study NCT05574049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The subjects will take once daily oromucosal strip with no drug on it for 90 days
Study NCT04289038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autogenic Relaxation
Description: Autogenic relaxation
Study NCT04289038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality game application
Description: virtual reality game application,
Study NCT04289038 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: kidney function narration
Description: kidney function narration
Study NCT06100601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ANS regulation therapy
Description: innovative intervention for functional dysphonia
Study NCT04742179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manteinance and care intervention on the green areas.
Description: Manteinance and care intervention on the green areas.
Study NCT04595279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking sessions
Description: Participants undergo topography and behavioral economic sessions where they can make choices to earn cigarette puffs by pulling plungers on experimental equipment
Study NCT02897414 — intervention group
Intervention type: OTHER
Intervention: Surveillance of state medical examiner databases
Study NCT06100601 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional voice therapy (CVT)
Description: conventional voice therapy traditionally provided for functional dysphonia
Study NCT06100601 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ANS regulation therapy + CVT
Description: combination of ANS regulation therapy and CVT
Study NCT05205876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eddii mobile application
Description: Participants will use the Eddii mobile application in the intervention arm.
Study NCT06447051 — intervention group
Intervention type: OTHER
Intervention: Kasai Surgery
Description: As per institute treatment protocol
Study NCT04606719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced Platelet Rich fibrin
Description: Preparing of A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes
Study NCT04606719 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Advanced Platelet Rich fibrin
Description: Preparing of A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes
Study NCT04606719 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Platelet Rich fibrin
Description: Preparing of A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes
Study NCT04926545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiao Chai Hu Tang (XCHT)
Description: XCHT 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, except the 1st cycle of chemotherapy for irinotecan used cohort patients.~Additional XCHT, 9g qd will be orally administrated for 4 days during the Round 0 study for irinotecan naive cohort patients.
Study NCT04926545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Raloxifene 60mg po, used as probe for pharmacokinetic testing. For irinotecan naive cohort patients, raloxifene 60mg will be orally administrated on Day 1 and Day 5 (4th day of XCHT administration) during round 0 study, Day 3 (the day before chemotherapy) during round 2 and round 3 study. For irinotecan used cohort patients, raloxifene 60mg will be orally administrated on Day 1 (irinotecan using day) during round 1 study, Day 4 (irinotecan using day) during round 2 study, and Day 3 (the day before chemotherapy) during round 3 study.
Study NCT04926545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Description: Patients will receive 3 cycles of FOLFIRI regimen for chemotherapy. Irinotecan intravenous (IV) infusion (180 mg/m2) through a drip into the bloodstream over 90 minutes. Folinic acid (400 mg/m2) IV infusion through a drip into the bloodstream over 2 hours. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) into the bloodstream over 5 minutes, followed by 5-FU (2400 mg/m2) continuous IV infusion through a drip or pump into the bloodstream for 46-48 hours.
Study NCT06392061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trilac
Description: Trilac® is a dietary supplement developed by Surveal Pharma to support digestive health and overall well-being. This probiotic contains 4 strains of naturally-occurring bacteria including: Lactobacillus acidophilus, LA-5®, Bifidobacterium animalis, BB-12®, Streptococcus thermophiles, STY-31 and Lactobacillus delbrueckii subsp. Bulgaricus LBY-27 in concentration of 4.5 milliards CFU/capsule. Patients in the probiotic group will be instructed to take one tablet per day for a period of 8 weeks.
Study NCT06132672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigators (peer navigator) training
Description: The Navigators training will be designed to increase knowledge and skills to help others (i.e., social network members). Navigators in the intervention group will be trained and supported for 12 months of implementation across years 3 and 4
Study NCT06132672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: delayed-intervention
Description: Those in the delayed-intervention group will be trained in year 5
Study NCT04917796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
Study NCT04917796 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Acupuncture
Description: Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
Study NCT06241443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hybrid simulation
Description: During the hybrid simulation, a student and a standardized patient participated. The patient wore a wearable pregnancy model. Before the start of the Natural Birth Approach Scenario, a pre-briefing session was conducted. The student's performance during the simulation was recorded on video, and each simulation lasted approximately 30 minutes. After the simulation, a debriefing session was held with the student, and feedback was given. Scales were used to evaluate the implementation of the practices.
Study NCT05176015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frenzel Lens
Description: pair of magnifying glasses (+20 dioptres) that are worn by the patient and an illuminating system. On using Frenzel goggles, the nystagmus is better seen as a result of eyes being magnified and inhibition of visual fixation.
Study NCT05176015 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Algorithm
Description: A diagnostic algorithm using the TiTrate approach: continuous, Intermittent, trigger or spontaneous.~The diagnostic algorithm use the REDCap software that include different videos to illustrate diagnostic tests and nystagmus types. Different maneuvers: HINTS+ battery, Dix-Hallpike test, Supine Roll test.~Different Particle Repositioning Techniques will be proposed according to specific tests: Epley and Gufoni maneuvers.~Risk Score is used to assess stroke risk for transient ischaemic attack (TIA): ABCD2 and the Canadian TIA Risk Score
Study NCT04908852 — intervention group
Intervention type: OTHER
Intervention: Blood Sample Collection - Observational Study
Description: Blood samples will be collected at enrollment and week 4 and used in analyses to understand associations between metabolic function and symptom experiences.